180 related articles for article (PubMed ID: 35139913)
1. Cytokine signatures differentiate systemic sclerosis patients at high versus low risk for pulmonary arterial hypertension.
Kolstad KD; Khatri A; Donato M; Chang SE; Li S; Steen VD; Utz PJ; Khatri P; Chung L
Arthritis Res Ther; 2022 Feb; 24(1):39. PubMed ID: 35139913
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): baseline characteristics and description of study population.
Hinchcliff M; Fischer A; Schiopu E; Steen VD;
J Rheumatol; 2011 Oct; 38(10):2172-9. PubMed ID: 21844142
[TBL] [Abstract][Full Text] [Related]
3. Combination of echocardiographic and pulmonary function test measures improves sensitivity for diagnosis of systemic sclerosis-associated pulmonary arterial hypertension: analysis of 2 cohorts.
Gladue H; Steen V; Allanore Y; Saggar R; Saggar R; Maranian P; Berrocal VJ; Avouac J; Meune C; Trivedi M; Khanna D
J Rheumatol; 2013 Oct; 40(10):1706-11. PubMed ID: 23950183
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Outcomes in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS).
Kolstad KD; Li S; Steen V; Chung L;
Chest; 2018 Oct; 154(4):862-871. PubMed ID: 29777655
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension.
Di Benedetto P; Guggino G; Manzi G; Ruscitti P; Berardicurti O; Panzera N; Grazia N; Badagliacca R; Riccieri V; Vizza CD; Radchenko G; Liakouli V; Ciccia F; Cipriani P; Giacomelli R
Arthritis Res Ther; 2020 Jun; 22(1):127. PubMed ID: 32487240
[TBL] [Abstract][Full Text] [Related]
6. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the pulmonary hypertension assessment and recognition of outcomes in scleroderma registry.
Chung L; Domsic RT; Lingala B; Alkassab F; Bolster M; Csuka ME; Derk C; Fischer A; Frech T; Furst DE; Gomberg-Maitland M; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TA; Molitor JA; Preston IR; Schiopu E; Shapiro L; Silver R; Simms R; Varga J; Gordon JK; Steen VD
Arthritis Care Res (Hoboken); 2014 Mar; 66(3):489-95. PubMed ID: 23983198
[TBL] [Abstract][Full Text] [Related]
7. In systemic sclerosis, the TAPSE/sPAP ratio can be used in addition to the DETECT algorithm for pulmonary arterial hypertension diagnosis.
Colalillo A; Grimaldi MC; Vaiarello V; Pellicano C; Leodori G; Gigante A; Romaniello A; Rosato E
Rheumatology (Oxford); 2022 May; 61(6):2450-2456. PubMed ID: 34605890
[TBL] [Abstract][Full Text] [Related]
8. Nailfold capillaroscopic changes in patients with idiopathic pulmonary arterial hypertension and systemic sclerosis-related pulmonary arterial hypertension.
Corrado A; Correale M; Mansueto N; Monaco I; Carriero A; Mele A; Colia R; Di Biase M; Cantatore FP
Microvasc Res; 2017 Nov; 114():46-51. PubMed ID: 28619664
[TBL] [Abstract][Full Text] [Related]
9. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.
Thakkar V; Stevens WM; Prior D; Moore OA; Byron J; Liew D; Patterson K; Hissaria P; Roddy J; Zochling J; Sahhar J; Nash P; Tymms K; Celermajer D; Gabbay E; Youssef P; Proudman SM; Nikpour M
Arthritis Res Ther; 2012 Jun; 14(3):R143. PubMed ID: 22691291
[TBL] [Abstract][Full Text] [Related]
10. Survival in systemic sclerosis-pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry.
Hinchcliff M; Khanna S; Hsu VM; Lee J; Almagor O; Chang RW; Steen V; Chung L;
Semin Arthritis Rheum; 2015 Dec; 45(3):309-14. PubMed ID: 26210782
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis.
Sanges S; Rice L; Tu L; Valenzi E; Cracowski JL; Montani D; Mantero JC; Ternynck C; Marot G; Bujor AM; Hachulla E; Launay D; Humbert M; Guignabert C; Lafyatis R
Ann Rheum Dis; 2023 Mar; 82(3):365-373. PubMed ID: 36600187
[TBL] [Abstract][Full Text] [Related]
12. Scleroderma pulmonary arterial hypertension: the same as idiopathic pulmonary arterial hypertension?
Khan SL; Mathai SC
Curr Opin Pulm Med; 2023 Sep; 29(5):380-390. PubMed ID: 37461869
[TBL] [Abstract][Full Text] [Related]
13. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study.
Coghlan JG; Denton CP; Grünig E; Bonderman D; Distler O; Khanna D; Müller-Ladner U; Pope JE; Vonk MC; Doelberg M; Chadha-Boreham H; Heinzl H; Rosenberg DM; McLaughlin VV; Seibold JR;
Ann Rheum Dis; 2014 Jul; 73(7):1340-9. PubMed ID: 23687283
[TBL] [Abstract][Full Text] [Related]
14. Idiopathic and Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: A Comparison of Demographic, Hemodynamic, and MRI Characteristics and Outcomes.
Ramjug S; Hussain N; Hurdman J; Billings C; Charalampopoulos A; Elliot CA; Kiely DG; Sabroe I; Rajaram S; Swift AJ; Condliffe R
Chest; 2017 Jul; 152(1):92-102. PubMed ID: 28223154
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial injury assessed with functional techniques in systemic sclerosis patients with pulmonary arterial hypertension versus systemic sclerosis patients without pulmonary arterial hypertension: a systematic review and meta-analysis.
Theodorakopoulou MP; Minopoulou I; Sarafidis P; Kamperidis V; Papadopoulos C; Dimitroulas T; Boutou AK
Rheumatol Int; 2021 Jun; 41(6):1045-1053. PubMed ID: 33830321
[TBL] [Abstract][Full Text] [Related]
16. Aberrant long-chain fatty acid metabolism associated with evolving systemic sclerosis-associated pulmonary arterial hypertension.
Coursen JC; Tuhy T; Naranjo M; Woods A; Hummers LK; Shah AA; Suresh K; Visovatti SH; Mathai SC; Hassoun PM; Damico RL; Simpson CE
Am J Physiol Lung Cell Mol Physiol; 2024 Jul; 327(1):L54-L64. PubMed ID: 38651694
[TBL] [Abstract][Full Text] [Related]
17. Soluble markers of B cell activation suggest a role of B cells in the pathogenesis of systemic sclerosis-associated pulmonary arterial hypertension.
Sanges S; Guerrier T; Duhamel A; Guilbert L; Hauspie C; Largy A; Balden M; Podevin C; Lefèvre G; Jendoubi M; Speca S; Hachulla É; Sobanski V; Dubucquoi S; Launay D
Front Immunol; 2022; 13():954007. PubMed ID: 35967377
[TBL] [Abstract][Full Text] [Related]
18. Differences in Right Ventricular Functional Changes during Treatment between Systemic Sclerosis-associated Pulmonary Arterial Hypertension and Idiopathic Pulmonary Arterial Hypertension.
Argula RG; Karwa A; Lauer A; Gregg D; Silver RM; Feghali-Bostwick C; Schanpp LM; Egbert K; Usher BW; Ramakrishnan V; Hassoun PM; Strange C
Ann Am Thorac Soc; 2017 May; 14(5):682-689. PubMed ID: 28282243
[TBL] [Abstract][Full Text] [Related]
19. Target organ expression and biomarker characterization of chemokine CCL21 in systemic sclerosis associated pulmonary arterial hypertension.
Didriksen H; Molberg Ø; Mehta A; Jordan S; Palchevskiy V; Fretheim H; Gude E; Ueland T; Brunborg C; Garen T; Midtvedt Ø; Andreassen AK; Lund-Johansen F; Distler O; Belperio J; Hoffmann-Vold AM
Front Immunol; 2022; 13():991743. PubMed ID: 36211384
[TBL] [Abstract][Full Text] [Related]
20. Kynurenine pathway metabolism evolves with development of preclinical and scleroderma-associated pulmonary arterial hypertension.
Simpson CE; Ambade AS; Harlan R; Roux A; Aja S; Graham D; Shah AA; Hummers LK; Hemnes AR; Leopold JA; Horn EM; Berman-Rosenzweig ES; Grunig G; Aldred MA; Barnard J; Comhair SAA; Tang WHW; Griffiths M; Rischard F; Frantz RP; Erzurum SC; Beck GJ; Hill NS; Mathai SC; Hassoun PM; Damico RL;
Am J Physiol Lung Cell Mol Physiol; 2023 Nov; 325(5):L617-L627. PubMed ID: 37786941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
